IMNM
vs
S&P 500
IMNM
S&P 500
Over the past 12 months, IMNM has significantly outperformed S&P 500, delivering a return of +95% compared to the S&P 500's +14% growth.
Stocks Performance
IMNM vs S&P 500
Performance Gap
IMNM vs S&P 500
Performance By Year
IMNM vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Immunome Inc
Glance View
Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. The company is headquartered in Exton, Pennsylvania and currently employs 39 full-time employees. The company went IPO on 2020-10-02. The firm's primary focus areas are oncology and infectious diseases. Its discovery platform identifies therapeutic antibodies and their targets by leveraging components of the immune system, memory B cells, from patients who have learned to fight off their disease. Its lead discovery programs include IMM-ONC-01 and IMM-BCP-01. IMM-ONC-01, is its lead oncology program, which is focused on IL-38. IMM-BCP-01, is its lead infectious disease discovery program with a focus on SARS-CoV-2, the virus that causes COVID-19. The firm is developing an antibody cocktail product candidate by identifying a combination of anti-viral antibodies produced by B cells from COVID-19 super-responders.